Randomized, Double-blind, Placebo-controlled, First-in-Human Study of GLPG2222 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2016
At a glance
- Drugs GLPG 2222 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Galapagos NV
- 28 Jul 2016 Status changed from recruiting to completed.
- 01 Jan 2016 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
- 11 Mar 2015 New trial record